<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="102567">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01977560</url>
  </required_header>
  <id_info>
    <org_study_id>201302095</org_study_id>
    <nct_id>NCT01977560</nct_id>
  </id_info>
  <brief_title>Diet and Exercise Intervention in Type 2 Diabetes</brief_title>
  <acronym>LID</acronym>
  <official_title>Diet and Exercise Intervention in Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Dairy Council</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>American Egg Board</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the effect of lifestyle intervention on metabolism
      and blood sugar control in Type 2 Diabetics.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2013</start_date>
  <primary_completion_date type="Anticipated">January 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Glycemic Control</measure>
    <time_frame>8 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>This aim will be evaluated by assessment of: i) fasting plasma glucose; ii) glycated hemoglobin (HbA1c); iii) use of diabetes medications and iv) resolution of Type 2 diabetes, defined as a fasting plasma glucose &lt;126 mg/dL, 2-hr oral glucose tolerance test plasma glucose &lt;200 mg/dL, HbA1c &lt;6.5% and discontinuation of all diabetes medications.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Glucose metabolism</measure>
    <time_frame>8 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Liver and skeletal muscle insulin sensitivity, β-cell function, and cellular factors in skeletal muscle and adipose tissue that regulate glucose metabolism</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neuronal Function</measure>
    <time_frame>8 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>This aim will be evaluated by assessing by administration of cognitive testing and brain MRI.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acceptability and Feasibility of Intervention</measure>
    <time_frame>8 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>This aim will be evaluated by using semi-structured interviews to assess accessibility and feasibility In addition, participants' time spent on intervention activities and delivery will be determined.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Cardiovascular risk factors</measure>
    <time_frame>8 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Plasma lipid profile; markers of inflammation, body fat distribution (visceral adipose tissue (VAT) intrahepatic triglyceride (IHTG) content and intramyocardial TG content), and cardiovascular structure and function</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>Standard Care</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>This arm will receive standard care for Type 2 diabetes: exercise and diet counseling according to the American Diabetes Association recommendations.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Optimum Lifestyle intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This arm will be participate in weekly visits with a dietitian and 4 weekly supervised exercise sessions. They will be advised to follow a high-protein, low-carbohydrate diet.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Optimum Lifestyle Intervention</intervention_name>
    <description>Participants will follow a high-protein, low-carbohydrate diet and participate in supervised exercise,</description>
    <arm_group_label>Optimum Lifestyle intervention</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Standard Care</intervention_name>
    <description>Participants will be given advice on exercise and the American Diabetes Association diet, as if they went to a Diabetes clinic.</description>
    <arm_group_label>Standard Care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age 30-64 yrs old

          2. BMI 28.0-42.0 kg/m2

          3. Diagnosis of type 2 diabetes based on HbA1C&gt;6.5% or results of an oral glucose
             tolerance test or current use of anti-diabetic medications

          4. Reported duration of type 2 diabetes &lt;8years

          5. HbA1C ≤8.5 %.

          6. Work at Washington University in St. Louis, Barnes Jewish Hospital or St. Louis
             Childrens Hospital.

        Exclusion Criteria:

          1. Diabetes therapy with long-acting Glucagon-like peptide-1 agonist (i.e. Bydureon),
             thiazolidinedione, or insulin

          2. Any change in diabetes medication in previous 3 months

          3. Unstable weight (&gt;2% change during the last 2 months before entering the study)

          4. History or evidence of serious pulmonary or cardiovascular disease, including acute
             coronary syndrome, heart failure requiring medications, or New York Heart Association
             class III heart failure (patients with marked limitation of activity and who are
             comfortable only at rest) or IV heart failure (patients who should be at complete
             rest, confined to bed or chair and who have discomfort with any physical activity).

          5. Evidence of serious cardiac abnormalities during exercise stress testing that
             increase cardiac risk of initiating an exercise program.

          6. Creatinine &gt;1.5 mg/dL

          7. Microalbuminuria; spot urine albumin:creatinine ratio &gt;30 (30 μg albumin/mg
             creatinine)

          8. Coagulation disorders

          9. Anemia (Hemoglobin &lt;10.0 g/dL)

         10. Liver enzymes (ALT and AST) ≥3 times the upper limit of normal

         11. Uncontrolled proliferative diabetic retinopathy

         12. Severe peripheral neuropathy diagnosed by monofilament testing

         13. Severe organ dysfunction

         14. Pregnant or breastfeeding

         15. Participating in regular exercise (&gt;1 h of structured exercise/week)

         16. Joint replacement within the last year

         17. Smokes tobacco

         18. Severe lactose intolerance

         19. Take any medication that might interfere with interpretation of the metabolic studies

         20. Unable or unwilling to follow the study protocol or for any reason the research team
             believes the volunteer is not an appropriate candidate for this study, including
             non-compliance with screening appointments or previous medical visits.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Samuel Klein, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Helene M Parker, BA</last_name>
    <phone>314-747-2627</phone>
    <email>hparker@dom.wustl.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mihoko Yoshino, MD, PhD</last_name>
    <phone>314-362-8228</phone>
    <email>myoshino@dom.wustl.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 23, 2014</lastchanged_date>
  <firstreceived_date>October 14, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Type 2 diabetes</keyword>
  <keyword>exercise</keyword>
  <keyword>high protein</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
